Hospitalization Became a Window for Smoking Treatment in Serious Mental Illness
Adults with serious mental illness who smoke daily often cycle through acute psychiatric care without ever getting a durable smoking cessation plan. The Helping HAND 3 randomized clinical trial tested whether the inpatient stay itself could be used to start a sustained, multicomponent intervention that carried forward after discharge. In a single hospital in Austin, Texas, investigators compared this approach with usual care in adults receiving inpatient psychiatric treatment between July 2015 and August 2019.
The rationale was straightforward and clinically familiar. Psychiatric hospitalization creates a rare stretch of daily contact with nurses, counselors, and treatment teams, which may lower the friction that often keeps smoking cessation care from reaching patients after discharge. For people living with serious mental illness, where tobacco dependence is common and quitting support is often fragmented, a brief intervention at the bedside is unlikely to be enough on its own. The trial therefore paired inpatient counseling with nicotine replacement access, proactive postdischarge counseling channels, and repeated outreach after discharge.
The enrolled population reflected that challenge. A total of 353 participants were randomized, and 342 were included in the analyses. Mean age was 35.8 years, mean cigarette consumption was 16.9 cigarettes per day, and nearly half of participants were women. Most participants were White and non-Hispanic. The study did not target a rarefied group of light smokers; it focused on daily smokers with psychiatric illness who were already in a setting where medical and behavioral instability can make quitting especially difficult.
Multicomponent Support Extended Beyond the Ward
Usual care consisted of brief smoking cessation information, self-help materials, advice from the admitting nurse, and an offer of nicotine replacement therapy during hospitalization. The sustained care intervention added four linked components meant to reduce the drop-off that usually follows discharge. Participants received inpatient motivational counseling, free transdermal nicotine patches at discharge, an offer of free postdischarge quitline, text-based, and/or web-based counseling, and postdischarge automated interactive voice response calls or text messages.
The design matters because each component addressed a different failure point in cessation care. Motivational counseling begins the behavioral shift while the patient is still under supervision. Nicotine patches reduce withdrawal when the person leaves the smoke-free hospital environment. Quitline, text, and web counseling create access beyond clinic hours and beyond the psychiatric unit. Automated calls or texts add a layer of persistence, which is often the difference between a one-time recommendation and an actual treatment course. In a population that may face cognitive symptoms, housing instability, or difficulty keeping appointments, passive referral alone is rarely enough.
The trial’s primary endpoint was biochemically verified 7-day point-prevalence abstinence at 6 months. That choice gave the study a hard clinical yardstick rather than a self-report-only endpoint. It also reflected a meaningful outcome for psychiatric care teams: whether a patient remained smoke-free after the acute hospitalization had passed and daily life had resumed.
Abstinence Rose, and Treatment Use Rose More Sharply
The sustained care approach produced a higher 6-month abstinence rate than usual care. Biochemically verified 7-day point-prevalence abstinence was 8.9% in the sustained care group and 3.5% in the usual care group, with an adjusted odds ratio of 2.95 and a 95% confidence interval of 1.24 to 6.99. The P value was .01. The number needed to treat was 18.5, with a wide confidence interval that ranged from 9.6 to 306.4.
One sentence captures the core result: abstinence nearly tripled, even though the absolute quit rate remained modest.
That pattern is clinically important in serious mental illness, where any durable movement in abstinence can be difficult to produce. Tobacco dependence is reinforced by withdrawal relief, habitual smoking routines, and the stress burden that often accompanies psychiatric illness. Intervening during hospitalization may work because it interrupts routine access to cigarettes, reduces immediate nicotine withdrawal, and gives patients a moment when treatment can be introduced without competing demands from work, transportation, or competing outpatient obligations.
The secondary outcome strengthens the signal. Over the 6 months after discharge, 74.6% of participants in the sustained care group reported using smoking cessation treatment, compared with 40.5% in the usual care group. The relative risk was 1.8, with a 95% confidence interval of 1.51 to 2.25, and the P value was less than .001. Treatment use is the mechanism that likely helps explain the abstinence difference. Patients cannot benefit from quitline counseling, text support, or nicotine replacement if they never start them. Here, the intervention did not merely ask people to quit; it increased the likelihood that they actually engaged with treatment after leaving the hospital.
Why the Strategy Fits Psychiatric Care
The results speak to a practical problem in inpatient psychiatry: discharge often severs the connection between motivation and follow-through. Patients may be willing to talk about quitting while hospitalized, yet the transition home can quickly erase that momentum. A sustained, multicomponent approach tries to bridge that gap by creating continuity across settings. The combination of counseling, pharmacotherapy access, and repeated postdischarge prompts is especially relevant for people whose illness burden can interfere with planning and self-activation.
The intervention also appears scalable. The components are familiar rather than exotic: motivational counseling, nicotine patches, quitline referral, text-based support, web support, and automated outreach. Those are tools health systems can potentially deploy without building an entirely new infrastructure. The trial therefore offers more than a proof of concept; it points to a model that can be embedded in routine psychiatric discharge planning.
Still, the findings come from one hospital in Austin, Texas, and from a group with a specific demographic profile. Generalizability to other psychiatric units, other regions, and more diverse populations will need confirmation. The absolute quit rate remained low, which is unsurprising in a high-risk population but still a reminder that even effective interventions leave many patients smoking. The confidence interval around the number needed to treat was wide, reflecting statistical uncertainty around how many patients must receive the program for one additional person to quit.
The trial was registered at ClinicalTrials.gov as NCT02204956, and its main contribution is clear in bedside terms: psychiatric hospitalization can serve as a real treatment entry point for tobacco dependence, not just a place to document it. For patients with serious mental illness, the discharge period is often where cessation plans fail. This intervention improved the odds that treatment would continue after the ward doors closed, and that continuity translated into more abstinence at 6 months.